Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
about
Melanized fungi in human diseaseFusarium infections in immunocompromised patientsCandida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsCandida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005Epidemiology of invasive candidiasis: a persistent public health problemNovel antifungal agents: a patent review (2013 - present).Treatment of cryptococcosis in the setting of HIV coinfection.Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts.Genotyping of Fusarium Isolates from Onychomycoses in Colombia: Detection of Two New Species Within the Fusarium solani Species Complex and In Vitro Antifungal Susceptibility Testing.Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.Synthesis and Antimicrobial Activities of His(2-aryl)-Arg and Trp-His(2-aryl) Classes of Dipeptidomimetics.Comparison of the Vitek 2 antifungal susceptibility system with the clinical and laboratory standards institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the SensitiMultiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, andFrequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.Process analysis of variables for standardization of antifungal susceptibility testing of nonfermentative yeasts.Voriconazole-Resistant Penicillium oxalicum: An Emerging Pathogen in Immunocompromised Hosts.A new model of in vitro fungal biofilms formed on human nail fragments allows reliable testing of laser and light therapies against onychomycosis.Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex.Multiple Scedosporium apiospermum abscesses in a woman survivor of a tsunami in northeastern Japan: a case report.Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infectionsCarbon assimilation profiles as a tool for identification of zygomycetesIn Vitro Triple Combination of Antifungal Drugs against Clinical Scopulariopsis and Microascus Species.In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus speciesIn vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.Treatment with intrastromal and intracameral voriconazole in 2 eyes with Lasiodiplodia theobromae keratitis: case reports.Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.Endogenous Candida endophthalmitis.Developments in the treatment of candidiasis: more choices and new challenges.Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.Detection of caspofungin resistance in Candida spp. by Etest.In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.The use of caspofungin in HIV-infected individuals.Posaconazole: a new broad-spectrum antifungal agent.Paecilomyces lilacinus infection in a liver transplant patient: case report and review of the literature.Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.Scedosporium apiospermum infection after near-drowning.Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis.Is azole resistance in Aspergillus fumigatus a problem in Spain?Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.
P2860
Q24633163-94DF078C-30D2-491D-BFDE-0B91EB1B482AQ24685627-1B562082-ACE5-431B-ACD2-2440EC09136CQ26863344-37B48CE1-7E92-4616-A784-1B6EB9450E62Q28260910-8EBBB197-7B77-410A-B77D-A6A96DD7C0A1Q29616758-C345D67E-B027-49CB-B847-1A5738E9A5AAQ30239745-D3E272F0-A95F-4F4F-AF72-6FBB9B0A22F1Q30366117-80967296-C708-43F1-80CC-6548C5E349E5Q30561825-886BB215-919E-41D9-8DDB-760215E6CD65Q31052986-34A3D65C-96A0-46D3-A1B9-A2A56CD55B57Q33490772-C5253650-99DA-46E1-A9EF-0FA545109850Q33791478-93A788F0-982C-49AD-9D3F-444952B7972FQ33827176-EE0D66C2-4AB6-4433-925F-047210D6A51AQ34309603-7A3153B2-AD21-4FB8-BEBB-3BD7FD4B4B49Q34737476-3639A85C-B2CF-4045-A762-130910D42C2DQ34737873-B7B2D58B-35BF-45AD-8543-F41C2F1DA938Q34802129-FF93D203-B4F1-4355-A9CB-0D682549EA89Q35485913-BCD3D1B6-9290-4C83-A7FF-B93971ABE19EQ35533576-F63B0723-EA74-4A8A-B9D5-922E0A18184FQ35571541-02658EBC-1A52-4972-8DFA-1225FD06C7B8Q35666612-B02BCA48-AF47-4826-B826-05100339D245Q35784447-5E4FC6AA-4908-4FD4-ADA3-95F41997CFECQ35859909-96DC413F-9297-4132-A51A-CC1C08494D70Q35960992-9B15AA5A-FC0E-4F8F-9318-A39D00B0876EQ36094852-0B453B90-B646-4D00-B828-62F1D2F0A733Q36152402-93A43C9C-2A9C-47A4-A991-DA083B7288DEQ36424929-A4E73A41-C328-4CDB-9696-289BA2BB8249Q36497888-F2EA1366-61DE-44D3-BF35-040D952B67D8Q36607424-CF339E58-4382-4143-B680-69F965AB10F0Q36623050-84D639A4-6A8A-4796-A0C5-94E6D8A3FC1EQ36744800-1685224C-6807-429A-8F8E-BE6F78CDDAF5Q36747567-07490B8A-50D3-40E0-990E-8F7CA6AE6EBFQ36803960-8BEBB50D-F902-41D8-84FD-5FA6DEA42D15Q36821383-4897E3EF-A1D8-457E-AAA8-FCE3E4D82E49Q36828159-D9929920-3885-460B-8C9C-C5619A6DF397Q36867452-493B7BA0-C7A1-4EB8-BB8D-297A5AB28B8BQ36870777-A630C4AD-7ACA-41D8-B6BB-EDDF50F2D475Q36917112-5E454908-E317-41FD-8793-FDEED6CDC2CAQ36933405-8408BF7B-BA91-4A06-8FA4-02B48EFF7322Q37026702-1D7D00B3-37F6-42B7-B844-1E9C15473E7AQ37048679-96C0386D-2EEC-4DAC-B1FE-58DB49D68A75
P2860
Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Head-to-head comparison of the ...... yeasts and filamentous fungi.
@en
type
label
Head-to-head comparison of the ...... yeasts and filamentous fungi.
@en
prefLabel
Head-to-head comparison of the ...... yeasts and filamentous fungi.
@en
P2093
P2860
P1476
Head-to-head comparison of the ...... f yeasts and filamentous fungi
@en
P2093
Alicia Gomez-Lopez
Araceli Monzon
Juan Luis Rodriguez-Tudela
Manuel Cuenca-Estrella
P2860
P304
P356
10.1128/AAC.50.3.917-921.2006
P407
P577
2006-03-01T00:00:00Z